prepared in collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
The aim of this Newsletter is to disseminate information on the safety and efficacy of pharmaceutical products, based on information received from our network of "drug information officers" and other sources such as specialized bulletins and journals, as well as partners in WHO. The information is produced in the form of résumés in English, full texts of which may be obtained on request from:
Quality Assurance and Safety:
World Health Organization,
1211 Geneva 27, Switzerland
E-mail address: email@example.com
Fax: +41 22 791 4730
Further information on adverse reactions may be obtained from the WHO Collaborating Centre for International Drug Monitoring, Stora Torget 3, S-753 20 Uppsala, Sweden
Internet:http://www.who-umc.org prepared in collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
News & Issues
This is the final issue of the newsletter for the year 2004. We hope that the information covered has been useful in your work and in keeping abreast of recent developments in drug safety. As stated in the previous issues, we have now established a system for electronic mailing of the newsletter to accommodate those of you who cannot be included in our postal mailing list. To join this list, please send an email to LISTSERV@WHO.INT with the message text: subscribe WHO-PHN.
This has been a busy year with many new priority areas emerging in drug safety. The World Alliance of Patient Safety was launched in October and the WHO drug safety programme will work closely with the Alliance, particularly in reporting medication errors and conducting research on the impact of safety measures in promoting patient safety solutions. The issue of safety of medicines in children, with emphasis on off-label use, is also recognized as an important and neglected area that needs to be brought to the attention of WHO.
The Twenty-seventh Annual Meeting of National Centres participating in the WHO Programme for International Drug Monitoring was held from 4 to 6 October, in Dublin, Ireland. We include, in this issue, the observations on the questions discussed by the working groups at the meeting. We hope these observations will stimulate innovative and collaborative approaches to pharmacovigilance. Last, but not least, we wish all our readers good health and happiness in 2005.